EGFR and neoplasm: Inter-group analysis of the FDGmax uptake at day 1 relative to baseline showed that one dose of Pan-HER therapy caused a significantly greater reduction in tumor metabolism than treatment with the vehicle (p ≤ 0.001), EGFR (p ≤ 0.01) or HER2 (p ≤ 0.01) antibody mixtures alone.